Products
Ulviprubart Biosimilar Monoclonal Antibody (KLRG1) for Research
Cat No.: GMP-Bios-INN-1437
Anti-KLRG1 therapeutic antibody (Pre-made Ulviprubart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Ulviprubart (development code ABC-008) is a humanized monoclonal antibody targeting KLRG1. It is developed by Abcuro for T-cell large granular lymphocytic leukemia, Inclusion body myositis in Phase II/III development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1437-1mg | 1mg | 3090 |
| GMP-Bios-INN-1437-10mg | 10mg | |
| GMP-Bios-INN-1437-100mg | 100mg | |
| GMP-Bios-INN-1437-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Ulviprubart biosimilar, Whole mAb, Anti-KLRG1 Antibody: Anti-KLRG1/Killer cell lectin-like receptor subfamily G member 1/C-type lectin domain family 15 member A/ITIM-containing receptor MAFA-L therapeutic antibody |
| INN Name | Ulviprubart |
| Target | KLRG1 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II/III |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2022 |
| Year Recommended | 2023 |
| Companies | Abcuro |
| Conditions Approved | na |
| Conditions Active | T-cell large granular lymphocytic leukemia;Inclusion body myositis |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
